Today: 9 June 2026
Rolls-Royce shares rebound after a wobble as investors size up the 2026 trade
22 January 2026
2 mins read

Rolls-Royce shares rebound after a wobble as investors size up the 2026 trade

London, Jan 22, 2026, 09:01 GMT

  • Rolls-Royce shares climbed roughly 0.8% in early trading, bouncing back from a 2% decline the previous day
  • Analysts highlight defence budgets and profit goals but warn that valuations appear stretched
  • The company has launched a £200 million interim share buyback program ahead of its results due on Feb. 26

Rolls-Royce shares climbed 0.8% to 1,264.5 pence in early London trading Thursday, rebounding after a 2.03% fall on Wednesday that closed the stock at £12.55. The dip came even as the FTSE 100 inched up 0.11%, with trading volume in Rolls-Royce staying below its recent average.

The modest rebound casts a sharp spotlight on a stock that’s come to symbolize the UK market’s aerospace and defence rally. Interactive Investor contributor Robert Stephens pointed out the Aerospace & Defence sector has jumped 91% over the past year, compared to a 20% rise for the broader market. He also highlighted Rolls-Royce’s forward price/earnings ratio of 44.2 — a stark contrast to the FTSE 350’s 18.7, reflecting higher expected earnings pricing.

Defence spending is shouldering much of the growth in trade. In June, NATO countries pledged to boost defence budgets to 2.8% of GDP by 2026, aiming for 5% by 2035, Reuters columnist Manishi Raychaudhuri reported. This shift comes as governments reallocate funds amid heightened geopolitical tensions.

The rally has sparked a wave of retail-style “what if” calculations. This week, Yahoo Finance and The Motley Fool revisited Rolls-Royce’s three-year stock performance, laying out various projections for where its share price might stand in 2026. https://uk.finance.yahoo.com/news/predicti… https://www.fool.co.uk/2026/01/20/see-how-…

Rolls-Royce is backing its shares with a £200 million interim buyback, kicked off on Jan. 2. The company plans to wrap up the repurchase by Feb. 24, just before it releases full-year results on Feb. 26.

Stephens noted the balance sheet has tightened dramatically, shifting from a net debt of £5.16 billion in 2021 to a net cash position of £1.08 billion by the company’s half-year results last June — with cash now surpassing borrowings.

He noted the company expects to hit operating profits around £3.75 billion by the 2028 financial year and suggested this growth trajectory might warrant a premium on the stock. “Rolls-Royce appears to offer an appealing risk/reward opportunity on a long-term view,” he wrote.

Analyst targets point to limited upside from here. Data from Investing.com indicates 19 analysts have an average 12-month price target of 1,242 pence, with forecasts stretching from 790 pence up to 1,625 pence.

On the sector radar, Stephens pointed to Chemring as another UK defence player, noting its cheaper valuation compared to Rolls-Royce’s higher multiple. Investors seem to be seeking growth but avoiding top-tier price tags.

The downside scenario is straightforward. A lofty multiple can “derate” — drop relative to earnings — if defense spending weakens, civil aviation demand slows, or investors conclude the stock already reflects years of positive news. Execution risk also lingers, since the premium assumes profits will continue rising.

Chief executive Tufan Erginbilgiç pointed to cost-cutting, contract adjustments, and improved engine performance as key to the turnaround. “We made great progress and we see a lot more potential,” he told reporters last year after the company raised its forecasts. https://www.reuters.com/business/aerospace…

Shares are still holding near their recent highs, with the 52-week peak around 1,306.5 pence. The key question now: will February’s results sustain the earnings momentum investors are expecting?

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”
Previous Story

BT share price jumps as Openreach steps up copper switch-off — UBS still says “sell”

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX
Next Story

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Go toTop